MedPath

Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

Phase 3
Recruiting
Conditions
Metastatic Malignant Neoplasm in the Brain
Interventions
Procedure: Brain Surgery
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Stereotactic Radiosurgery
Registration Number
NCT05438212
Lead Sponsor
NRG Oncology
Brief Summary

This phase III trial compares the usual treatment of surgery after stereotactic radiosurgery (SRS) to receiving SRS before surgery in treating patients with cancer that has spread to the brain (brain metastases). Stereotactic radiosurgery is a type of radiation therapy that delivers a high dose of radiation to target tumors and minimizes effect on normal surrounding brain tissue. The combination of surgery and radiation may stop the tumor from growing for a few months or longer and may reduce symptoms of brain metastases. This study investigates whether treating with SRS before surgery may be better than SRS after surgery in reducing the possibility of the tumor coming back, reducing or preventing the cancer from spreading to other areas of the brain and reducing the risk of scarring on the brain from radiation.

Detailed Description

PRIMARY OBJECTIVE:

I. To determine if the time to composite adverse endpoint (CAE) (defined as: 1) local tumor progression within the surgical bed; and/or 2) adverse radiation effect \[ARE\], the imaging correlate of post-stereotactic radiosurgery \[SRS\] radiation necrosis; and/or 3) nodular meningeal disease \[nMD\]) is improved in patients treated with pre-resection SRS to the intact lesion versus those treated with post-resection SRS.

SECONDARY OBJECTIVES:

I. To assess the trajectory of symptom burden in patients treated with pre-resection SRS to the intact lesion versus those treated to the post-resection surgical cavity as measured by MD Anderson Symptom Inventory for brain tumor (MDASI-BT).

II. To determine whether there is improved overall survival (OS) in patients with resected brain metastases who undergo pre-resection SRS compared to patients who receive post-resection SRS.

III. To compare rates of ARE, the imaging correlate of radiation necrosis, in patients who receive pre-resection SRS to patients who receive post-resection SRS.

IV. To determine whether there is increased time to whole brain radiotherapy (WBRT) in patients who receive pre-resection SRS compared to patients who receive post-resection SRS.

V. To assess the trajectory of neuro-cognitive function in patients treated with pre-resection SRS to the intact lesion versus those treated to the post-resection surgical cavity as measured by the Montreal Cognitive Assessment (MoCA).

VI. To compare rates of nodular meningeal disease in patients who receive pre-resection SRS to patients who receive post-resection SRS.

VII. To compare rates of local recurrence in the resection cavity for patients who receive pre-resection SRS to patients who receive post-resection SRS.

VIII. To compare rates of local recurrence of intact, non-index metastases treated with SRS.

IX. To compare rates of distant brain failure in patients who receive pre-resection SRS to patients who receive post-resection SRS.

X. To assess toxicity in the two treatment arms.

EXPLORATORY OBJECTIVE:

I. To explore if the type of surgical resection (piece-meal versus \[vs.\] en-bloc) may be associated with the rate of nodular meningeal disease.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients undergo surgery per standard of care. Within 10-30 days after surgery, patients undergo stereotactic radiosurgery for 1 fraction.

ARM II: Within 7 days before surgery, patients undergo stereotactic radiosurgery for 1 fraction. Patients undergo surgery per standard of care.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for additional 2 years.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
236
Inclusion Criteria
  • Radiographic confirmation of 1-4 brain metastases, one of which requires resection, as defined by magnetic resonance imaging (MRI) with contrast obtained within 14 days prior to registration

    • The maximum diameter of the lesion to be resected on the post-contrast MRI, as measured on any orthogonal plane (axial, sagittal, coronal), must measure >= 2.0 cm and =< 5.0 cm.
    • The maximum diameter of any lesions which will not be resected must be =< 4.0 cm in maximum diameter
  • Known active or history of invasive non-central nervous system (CNS) primary cancer based on documented pathologic diagnosis within the past 3 years

  • All brain metastases must be located >= 5 mm from the optic chiasm and outside the brainstem

  • Patient is able to medically tolerate surgery and SRS

  • Lesions chosen for surgical therapy must be deemed appropriate targets for safe, gross total resection by the treating surgeon

  • History/physical examination within 14 days prior to registration

  • Age >= 18

  • Karnofsky performance status (KPS) >= 60 within 14 days prior to registration

  • A negative urine or serum pregnancy test (in persons of childbearing potential) within =< 14 days prior to registration. Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal

  • Participants who are sexually active must agree to use medically acceptable forms of contraception during treatment on this study to prevent pregnancy

  • The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information

Exclusion Criteria
  • Prior cranial radiotherapy, including whole brain radiotherapy, or SRS to the resection site

    • Note: The index lesion to be resected cannot have been previously treated with SRS (i.e. repeat radiosurgery to the same location/lesion is not allowed on this protocol). Previous SRS to other lesions is allowed
  • Evidence of leptomeningeal disease (LMD)

    • Note: For the purposes of exclusion, LMD is a clinical diagnosis, defined as positive cerebrospinal fluid (CSF) cytology and/or unequivocal radiologic or clinical evidence of leptomeningeal involvement. Patients with leptomeningeal symptoms in the setting of leptomeningeal enhancement by imaging (MRI) would be considered to have LMD even in the absence of positive CSF cytology. In contrast, an asymptomatic or minimally symptomatic patient with mild or nonspecific leptomeningeal enhancement (MRI) would not be considered to have LMD. In that patient, CSF sampling is not required to formally exclude LMD, but can be performed at the investigator's discretion based on level of clinical suspicion
  • Any medical conditions which would make this protocol unreasonably hazardous, including, but not limited to: contraindications to general endotracheal anesthesia; intracranial surgery; and stereotactic radiosurgery

  • Primary histology of germ cell tumor, small cell carcinoma or lymphoma

  • More than one brain metastasis planned for resection

  • Inability to undergo MRI with contrast

  • Planned administration of cytotoxic chemotherapy or tyrosine/multi-kinase inhibitors within the 3 days prior to, the day of, or within 3 days after the completion of SRS

    • Note: chemotherapy and immunotherapy outside of this window are allowed

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm I (surgery, stereotactic radiosurgery)Questionnaire AdministrationPatients undergo surgery per standard of care. Within 10-30 days after surgery, patients undergo stereotactic radiosurgery for 1 fraction.
Arm II (stereotactic radiosurgery, surgery)Brain SurgeryWithin 7 days before surgery, patients undergo stereotactic radiosurgery for 1 fraction. Patients undergo surgery per standard of care.
Arm I (surgery, stereotactic radiosurgery)Quality-of-Life AssessmentPatients undergo surgery per standard of care. Within 10-30 days after surgery, patients undergo stereotactic radiosurgery for 1 fraction.
Arm I (surgery, stereotactic radiosurgery)Stereotactic RadiosurgeryPatients undergo surgery per standard of care. Within 10-30 days after surgery, patients undergo stereotactic radiosurgery for 1 fraction.
Arm II (stereotactic radiosurgery, surgery)Quality-of-Life AssessmentWithin 7 days before surgery, patients undergo stereotactic radiosurgery for 1 fraction. Patients undergo surgery per standard of care.
Arm II (stereotactic radiosurgery, surgery)Questionnaire AdministrationWithin 7 days before surgery, patients undergo stereotactic radiosurgery for 1 fraction. Patients undergo surgery per standard of care.
Arm I (surgery, stereotactic radiosurgery)Brain SurgeryPatients undergo surgery per standard of care. Within 10-30 days after surgery, patients undergo stereotactic radiosurgery for 1 fraction.
Arm II (stereotactic radiosurgery, surgery)Stereotactic RadiosurgeryWithin 7 days before surgery, patients undergo stereotactic radiosurgery for 1 fraction. Patients undergo surgery per standard of care.
Primary Outcome Measures
NameTimeMethod
Time to composite adverse endpoint (CAE)Time from surgery (with the post-operative MRI as the 'baseline' for purposes of disease assessment) to local tumor progression (within the surgical bed), nodular meningeal disease, or radiation necrosis, whichever occurs first, assessed up to 4 years

Analysis for this endpoint will consist of testing the cause-specific hazard ratio in a Cox proportional hazards model.

Secondary Outcome Measures
NameTimeMethod
Overall survival (OS)Time from randomization to death due to any cause, assessed up to 4 years

Analysis for this endpoint will consist of estimation of the OS distribution of each treatment arm via the Kaplan-Meier method and a stratified log-rank test.

Rate of local tumor progressionUp to 4 years

The time origin for these imaging-based endpoints will be time of surgery (with the post-operative magnetic resonance imaging \[MRI\] as the 'baseline' for purposes of disease assessment). These analyses will involve estimating the cumulative incidence function of local progression, radiation necrosis, nodular meningeal disease, and distant brain failures in the presence of competing event of deaths. The Gray's test will be used to evaluate the difference in the distribution of local progression between treatment arms.

Rate of radiation necrosisUp to 4 years

The time origin for these imaging-based endpoints will be time of surgery (with the post-operative MRI as the 'baseline' for purposes of disease assessment). These analyses will involve estimating the cumulative incidence function of local progression, radiation necrosis, nodular meningeal disease, and distant brain failures in the presence of competing event of deaths. The Gray's test will be used to evaluate the difference in the distribution of radiation necrosis between treatment arms.

Rate of nodular meningeal diseaseUp to 4 years

The time origin for these imaging-based endpoints will be time of surgery (with the post-operative MRI as the 'baseline' for purposes of disease assessment). These analyses will involve estimating the cumulative incidence function of local progression, radiation necrosis, nodular meningeal disease, and distant brain failures in the presence of competing event of deaths. The Gray's test will be used to evaluate the difference in the distribution of nodular meningeal disease between treatment arms.

Rate of distant brain failuresUp to 4 years

The time origin for these imaging-based endpoints will be time of surgery (with the post-operative MRI as the 'baseline' for purposes of disease assessment). These analyses will involve estimating the cumulative incidence function of local progression, radiation necrosis, nodular meningeal disease, and distant brain failures in the presence of competing event of deaths. The Gray's test will be used to evaluate the difference in the distribution of distant brain failures between treatment arms.

Frequency of adverse events (AEs)Up to 4 years

AEs will be graded according to Common Terminology Criteria for Adverse Events version 5.0. Comprehensive summaries of all AEs by treatment arm will be generated and examined. Counts and frequencies of worst (highest score) AE per patient will be presented overall and by AE type category, separately by assigned treatment group. The proportion of patients with at least one grade 3 or higher AE will be compared between treatment arms. Any frequencies to be tested will be evaluated using the chi-square or exact test as appropriate, with two-sided significance level 0.05.

Change in MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT)Baseline up to 2 years after surgery

Will implement mixed effects models for repeated measures to evaluate the MDASI-BT scores longitudinally.

Change in cognitive functionBaseline up to 2 years after surgery

Measured by Montreal Cognitive Assessment (MoCA). Will implement mixed effects models for repeated measures to evaluate the MoCA scores longitudinally.

Trial Locations

Locations (191)

Piedmont Hospital

🇺🇸

Atlanta, Georgia, United States

Saint Joseph's Hospital and Medical Center

🇺🇸

Phoenix, Arizona, United States

Banner University Medical Center - Tucson

🇺🇸

Tucson, Arizona, United States

University of Arizona Cancer Center-North Campus

🇺🇸

Tucson, Arizona, United States

Kaiser Permanente-Anaheim

🇺🇸

Anaheim, California, United States

Sutter Auburn Faith Hospital

🇺🇸

Auburn, California, United States

Sutter Cancer Centers Radiation Oncology Services-Auburn

🇺🇸

Auburn, California, United States

Kaiser Permanente-Bellflower

🇺🇸

Bellflower, California, United States

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

🇺🇸

Irvine, California, United States

Kaiser Permanente Los Angeles Medical Center

🇺🇸

Los Angeles, California, United States

Memorial Medical Center

🇺🇸

Modesto, California, United States

Kaiser Permanente-Ontario

🇺🇸

Ontario, California, United States

Saint Joseph Hospital - Orange

🇺🇸

Orange, California, United States

UC Irvine Health/Chao Family Comprehensive Cancer Center

🇺🇸

Orange, California, United States

Stanford Cancer Institute Palo Alto

🇺🇸

Palo Alto, California, United States

Sutter Cancer Centers Radiation Oncology Services-Roseville

🇺🇸

Roseville, California, United States

Sutter Roseville Medical Center

🇺🇸

Roseville, California, United States

Sutter Medical Center Sacramento

🇺🇸

Sacramento, California, United States

University of California Davis Comprehensive Cancer Center

🇺🇸

Sacramento, California, United States

California Pacific Medical Center-Pacific Campus

🇺🇸

San Francisco, California, United States

UCSF Medical Center-Parnassus

🇺🇸

San Francisco, California, United States

Sutter Pacific Medical Foundation

🇺🇸

Santa Rosa, California, United States

Sutter Solano Medical Center/Cancer Center

🇺🇸

Vallejo, California, United States

UM Sylvester Comprehensive Cancer Center at Coral Gables

🇺🇸

Coral Gables, Florida, United States

UM Sylvester Comprehensive Cancer Center at Deerfield Beach

🇺🇸

Deerfield Beach, Florida, United States

Mayo Clinic in Florida

🇺🇸

Jacksonville, Florida, United States

University of Miami Miller School of Medicine-Sylvester Cancer Center

🇺🇸

Miami, Florida, United States

Miami Cancer Institute

🇺🇸

Miami, Florida, United States

Moffitt Cancer Center-International Plaza

🇺🇸

Tampa, Florida, United States

Moffitt Cancer Center - McKinley Campus

🇺🇸

Tampa, Florida, United States

Moffitt Cancer Center

🇺🇸

Tampa, Florida, United States

Moffitt Cancer Center at Wesley Chapel

🇺🇸

Wesley Chapel, Florida, United States

Grady Health System

🇺🇸

Atlanta, Georgia, United States

Emory University Hospital Midtown

🇺🇸

Atlanta, Georgia, United States

Emory University Hospital/Winship Cancer Institute

🇺🇸

Atlanta, Georgia, United States

Emory Saint Joseph's Hospital

🇺🇸

Atlanta, Georgia, United States

Advocate Outpatient Center - Aurora

🇺🇸

Aurora, Illinois, United States

Advocate Good Shepherd Hospital

🇺🇸

Barrington, Illinois, United States

Centralia Oncology Clinic

🇺🇸

Centralia, Illinois, United States

Northwestern University

🇺🇸

Chicago, Illinois, United States

University of Chicago Comprehensive Cancer Center

🇺🇸

Chicago, Illinois, United States

AMG Crystal Lake - Oncology

🇺🇸

Crystal Lake, Illinois, United States

Carle at The Riverfront

🇺🇸

Danville, Illinois, United States

Cancer Care Specialists of Illinois - Decatur

🇺🇸

Decatur, Illinois, United States

Decatur Memorial Hospital

🇺🇸

Decatur, Illinois, United States

Advocate Good Samaritan Hospital

🇺🇸

Downers Grove, Illinois, United States

Carle Physician Group-Effingham

🇺🇸

Effingham, Illinois, United States

Crossroads Cancer Center

🇺🇸

Effingham, Illinois, United States

Elmhurst Memorial Hospital

🇺🇸

Elmhurst, Illinois, United States

Advocate South Suburban Hospital

🇺🇸

Hazel Crest, Illinois, United States

AMG Libertyville - Oncology

🇺🇸

Libertyville, Illinois, United States

Carle Physician Group-Mattoon/Charleston

🇺🇸

Mattoon, Illinois, United States

Edward Hospital/Cancer Center

🇺🇸

Naperville, Illinois, United States

UC Comprehensive Cancer Center at Silver Cross

🇺🇸

New Lenox, Illinois, United States

Cancer Care Center of O'Fallon

🇺🇸

O'Fallon, Illinois, United States

Advocate Christ Medical Center

🇺🇸

Oak Lawn, Illinois, United States

Advocate Lutheran General Hospital

🇺🇸

Park Ridge, Illinois, United States

Southern Illinois University School of Medicine

🇺🇸

Springfield, Illinois, United States

Springfield Clinic

🇺🇸

Springfield, Illinois, United States

Springfield Memorial Hospital

🇺🇸

Springfield, Illinois, United States

Carle Cancer Center

🇺🇸

Urbana, Illinois, United States

Northwestern Medicine Cancer Center Warrenville

🇺🇸

Warrenville, Illinois, United States

Ascension Saint Vincent Indianapolis Hospital

🇺🇸

Indianapolis, Indiana, United States

UI Health Care Mission Cancer and Blood - Ankeny Clinic

🇺🇸

Ankeny, Iowa, United States

UI Health Care Mission Cancer and Blood - West Des Moines Clinic

🇺🇸

Clive, Iowa, United States

Iowa Methodist Medical Center

🇺🇸

Des Moines, Iowa, United States

UI Health Care Mission Cancer and Blood - Des Moines Clinic

🇺🇸

Des Moines, Iowa, United States

UI Health Care Mission Cancer and Blood - Laurel Clinic

🇺🇸

Des Moines, Iowa, United States

UI Health Care Mission Cancer and Blood - Waukee Clinic

🇺🇸

Waukee, Iowa, United States

University of Maryland/Greenebaum Cancer Center

🇺🇸

Baltimore, Maryland, United States

UM Baltimore Washington Medical Center/Tate Cancer Center

🇺🇸

Glen Burnie, Maryland, United States

University of Michigan Comprehensive Cancer Center

🇺🇸

Ann Arbor, Michigan, United States

Wayne State University/Karmanos Cancer Institute

🇺🇸

Detroit, Michigan, United States

Weisberg Cancer Treatment Center

🇺🇸

Farmington Hills, Michigan, United States

Corewell Health William Beaumont University Hospital

🇺🇸

Royal Oak, Michigan, United States

Corewell Health Beaumont Troy Hospital

🇺🇸

Troy, Michigan, United States

Essentia Health Saint Joseph's Medical Center

🇺🇸

Brainerd, Minnesota, United States

Essentia Health - Deer River Clinic

🇺🇸

Deer River, Minnesota, United States

Essentia Health Cancer Center

🇺🇸

Duluth, Minnesota, United States

Essentia Health Saint Mary's Medical Center

🇺🇸

Duluth, Minnesota, United States

Miller-Dwan Hospital

🇺🇸

Duluth, Minnesota, United States

Essentia Health Hibbing Clinic

🇺🇸

Hibbing, Minnesota, United States

Coborn Cancer Center at Saint Cloud Hospital

🇺🇸

Saint Cloud, Minnesota, United States

Essentia Health Sandstone

🇺🇸

Sandstone, Minnesota, United States

Essentia Health Virginia Clinic

🇺🇸

Virginia, Minnesota, United States

Parkland Health Center - Farmington

🇺🇸

Farmington, Missouri, United States

Saint Luke's Hospital of Kansas City

🇺🇸

Kansas City, Missouri, United States

Missouri Baptist Medical Center

🇺🇸

Saint Louis, Missouri, United States

Sainte Genevieve County Memorial Hospital

🇺🇸

Sainte Genevieve, Missouri, United States

Mercy Hospital Springfield

🇺🇸

Springfield, Missouri, United States

Missouri Baptist Sullivan Hospital

🇺🇸

Sullivan, Missouri, United States

BJC Outpatient Center at Sunset Hills

🇺🇸

Sunset Hills, Missouri, United States

Billings Clinic Cancer Center

🇺🇸

Billings, Montana, United States

Benefis Sletten Cancer Institute

🇺🇸

Great Falls, Montana, United States

Renown Regional Medical Center

🇺🇸

Reno, Nevada, United States

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

🇺🇸

Lebanon, New Hampshire, United States

Cooper Hospital University Medical Center

🇺🇸

Camden, New Jersey, United States

Saint Barnabas Medical Center

🇺🇸

Livingston, New Jersey, United States

Rutgers Cancer Institute of New Jersey

🇺🇸

New Brunswick, New Jersey, United States

Newark Beth Israel Medical Center

🇺🇸

Newark, New Jersey, United States

The Valley Hospital - Luckow Pavilion

🇺🇸

Paramus, New Jersey, United States

Capital Health Medical Center-Hopewell

🇺🇸

Pennington, New Jersey, United States

Valley Health System Ridgewood Campus

🇺🇸

Ridgewood, New Jersey, United States

Community Medical Center

🇺🇸

Toms River, New Jersey, United States

Valley Health System-Hematology/Oncology

🇺🇸

Westwood, New Jersey, United States

Montefiore Medical Center-Einstein Campus

🇺🇸

Bronx, New York, United States

Montefiore Medical Center-Weiler Hospital

🇺🇸

Bronx, New York, United States

Montefiore Medical Center - Moses Campus

🇺🇸

Bronx, New York, United States

New York-Presbyterian/Brooklyn Methodist Hospital

🇺🇸

Brooklyn, New York, United States

Roswell Park Cancer Institute

🇺🇸

Buffalo, New York, United States

The New York Hospital Medical Center of Queens

🇺🇸

Flushing, New York, United States

Northern Westchester Hospital

🇺🇸

Mount Kisco, New York, United States

Mount Sinai Chelsea

🇺🇸

New York, New York, United States

Mount Sinai West

🇺🇸

New York, New York, United States

Mount Sinai Hospital

🇺🇸

New York, New York, United States

NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

🇺🇸

New York, New York, United States

Manhattan Eye Ear and Throat Hospital

🇺🇸

New York, New York, United States

NYP/Weill Cornell Medical Center

🇺🇸

New York, New York, United States

Lenox Hill Hospital

🇺🇸

New York, New York, United States

University of Rochester

🇺🇸

Rochester, New York, United States

Stony Brook University Medical Center

🇺🇸

Stony Brook, New York, United States

Good Samaritan University Hospital

🇺🇸

West Islip, New York, United States

Carolinas Medical Center/Levine Cancer Institute

🇺🇸

Charlotte, North Carolina, United States

Atrium Health Cabarrus/LCI-Concord

🇺🇸

Concord, North Carolina, United States

CaroMont Regional Medical Center

🇺🇸

Gastonia, North Carolina, United States

Novant Health Cancer Institute Radiation Oncology - Wilmington

🇺🇸

Wilmington, North Carolina, United States

Wake Forest University Health Sciences

🇺🇸

Winston-Salem, North Carolina, United States

Sanford Broadway Medical Center

🇺🇸

Fargo, North Dakota, United States

Sanford Roger Maris Cancer Center

🇺🇸

Fargo, North Dakota, United States

Indu and Raj Soin Medical Center

🇺🇸

Beavercreek, Ohio, United States

Case Western Reserve University

🇺🇸

Cleveland, Ohio, United States

Ohio State University Comprehensive Cancer Center

🇺🇸

Columbus, Ohio, United States

Riverside Methodist Hospital

🇺🇸

Columbus, Ohio, United States

Grant Medical Center

🇺🇸

Columbus, Ohio, United States

Delaware Health Center-Grady Cancer Center

🇺🇸

Delaware, Ohio, United States

Grady Memorial Hospital

🇺🇸

Delaware, Ohio, United States

Kettering Medical Center

🇺🇸

Kettering, Ohio, United States

Mercy Health - Perrysburg Hospital

🇺🇸

Perrysburg, Ohio, United States

University of Oklahoma Health Sciences Center

🇺🇸

Oklahoma City, Oklahoma, United States

Northeast Radiation Oncology Center

🇺🇸

Dunmore, Pennsylvania, United States

Penn State Milton S Hershey Medical Center

🇺🇸

Hershey, Pennsylvania, United States

Thomas Jefferson University Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

UPMC-Presbyterian Hospital

🇺🇸

Pittsburgh, Pennsylvania, United States

UPMC-Shadyside Hospital

🇺🇸

Pittsburgh, Pennsylvania, United States

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

Gibbs Cancer Center-Gaffney

🇺🇸

Gaffney, South Carolina, United States

Gibbs Cancer Center-Pelham

🇺🇸

Greer, South Carolina, United States

Spartanburg Medical Center

🇺🇸

Spartanburg, South Carolina, United States

SMC Center for Hematology Oncology Union

🇺🇸

Union, South Carolina, United States

Sanford Cancer Center Oncology Clinic

🇺🇸

Sioux Falls, South Dakota, United States

Sanford USD Medical Center - Sioux Falls

🇺🇸

Sioux Falls, South Dakota, United States

The Children's Hospital at TriStar Centennial

🇺🇸

Nashville, Tennessee, United States

Covenant Medical Center-Lakeside

🇺🇸

Lubbock, Texas, United States

University of Texas Health Science Center at San Antonio

🇺🇸

San Antonio, Texas, United States

Huntsman Cancer Institute/University of Utah

🇺🇸

Salt Lake City, Utah, United States

Inova Schar Cancer Institute

🇺🇸

Fairfax, Virginia, United States

Henrico Doctor's Hospital

🇺🇸

Richmond, Virginia, United States

CJW Medical Center - Johnston-Willis Campus

🇺🇸

Richmond, Virginia, United States

Virginia Commonwealth University/Massey Cancer Center

🇺🇸

Richmond, Virginia, United States

Carilion Roanoke Memorial Hospital

🇺🇸

Roanoke, Virginia, United States

ThedaCare Regional Cancer Center

🇺🇸

Appleton, Wisconsin, United States

Duluth Clinic Ashland

🇺🇸

Ashland, Wisconsin, United States

Northwest Wisconsin Cancer Center

🇺🇸

Ashland, Wisconsin, United States

Aurora Cancer Care-Southern Lakes VLCC

🇺🇸

Burlington, Wisconsin, United States

Aurora Health Care Germantown Health Center

🇺🇸

Germantown, Wisconsin, United States

Aurora Cancer Care-Grafton

🇺🇸

Grafton, Wisconsin, United States

Aurora BayCare Medical Center

🇺🇸

Green Bay, Wisconsin, United States

Essentia Health-Hayward Clinic

🇺🇸

Hayward, Wisconsin, United States

Aurora Cancer Care-Kenosha South

🇺🇸

Kenosha, Wisconsin, United States

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center

🇺🇸

Madison, Wisconsin, United States

University of Wisconsin Carbone Cancer Center - University Hospital

🇺🇸

Madison, Wisconsin, United States

Aurora Cancer Care-Milwaukee

🇺🇸

Milwaukee, Wisconsin, United States

Aurora Saint Luke's Medical Center

🇺🇸

Milwaukee, Wisconsin, United States

Medical College of Wisconsin

🇺🇸

Milwaukee, Wisconsin, United States

Aurora Sinai Medical Center

🇺🇸

Milwaukee, Wisconsin, United States

Vince Lombardi Cancer Clinic - Oshkosh

🇺🇸

Oshkosh, Wisconsin, United States

Aurora Cancer Care-Racine

🇺🇸

Racine, Wisconsin, United States

Aspirus Cancer Care - James Beck Cancer Center

🇺🇸

Rhinelander, Wisconsin, United States

Vince Lombardi Cancer Clinic-Sheboygan

🇺🇸

Sheboygan, Wisconsin, United States

Essentia Health-Spooner Clinic

🇺🇸

Spooner, Wisconsin, United States

Aspirus Cancer Care - Stevens Point

🇺🇸

Stevens Point, Wisconsin, United States

Aurora Medical Center in Summit

🇺🇸

Summit, Wisconsin, United States

Essentia Health Saint Mary's Hospital - Superior

🇺🇸

Superior, Wisconsin, United States

UW Cancer Center at ProHealth Care

🇺🇸

Waukesha, Wisconsin, United States

Aspirus Regional Cancer Center

🇺🇸

Wausau, Wisconsin, United States

Aurora Cancer Care-Milwaukee West

🇺🇸

Wauwatosa, Wisconsin, United States

Aurora West Allis Medical Center

🇺🇸

West Allis, Wisconsin, United States

Aspirus Cancer Care - Wisconsin Rapids

🇺🇸

Wisconsin Rapids, Wisconsin, United States

CHUM - Centre Hospitalier de l'Universite de Montreal

🇨🇦

Montreal, Quebec, Canada

The Research Institute of the McGill University Health Centre (MUHC)

🇨🇦

Montreal, Quebec, Canada

CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)

🇨🇦

Quebec City, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath